Le secteur de cytologie est rattaché à l’équipe du Pr Mahon – Inserm U916 – à l’institut Bergonié.
Le secteur d’hémostase travaille en étroite interaction avec l'unité de recherche Inserm (INSERM Unité 1034) localisée sur le site Haut-Lévêque

Publications récentes du service (2015)

Allou, K., Vial, J.P., Bene, M.C. & Lacombe, F. (2015) The routine leukocyte differential flow cytometry HematoFlow method: A new flagging system for automatic validation. Cytometry B Clin Cytom.

Bidet, A., Dulucq, S. & Aladjidi, N. (2015) Transient abnormal myelopoiesis (TAM) in a neonate without Down syndrome. Br J Haematol, 168, 2.

Etienne, G., Dulucq, S., Lascaux, A., Schmitt, A., Bidet, A., Fort, M.P., Lippert, E., Bureau, C., Adiko, D., Hayette, S., Reiffers, J., Nicolini, F.E. & Mahon, F.X. (2015) ELN 2013 response status criteria: relevance for de novo imatinib chronic phase chronic myeloid leukemia patients? Am J Hematol, 90, 37-41.

Freyburger, G., Labrouche, S., Hubert, C. & Bauduer, F. (2015) Haemostaseome-associated SNPs: has the thrombotic phenotype a greater influence than ethnicity? GMT study from Aquitaine including Basque individuals. Thromb Haemost, 113, 66-76.

Gioia, R., Tregoat, C., Dumas, P.Y., Lagarde, V., Prouzet-Mauleon, V., Desplat, V., Sirvent, A., Praloran, V., Lippert, E., Villacreces, A., Leconet, W., Robert, B., Vigon, I., Roche, S., Mahon, F.X. & Pasquet, J.M. (2015) CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia. J Pathol, 237, 14-24.

Mammadova-Bach, E., Ollivier, V., Loyau, S., Schaff, M., Dumont, B., Favier, R., Freyburger, G., Latger-Cannard, V., Nieswandt, B., Gachet, C., Mangin, P.H. & Jandrot-Perrus, M. (2015) Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. Blood, 126, 683-691.

Nasr, R.R., Hmadi, R.A., El-Eit, R.M., Iskandarani, A.N., Jabbour, M.N., Zaatari, G.S., Mahon, F.X., Pisano, C.C. & Darwiche, N.D. (2015) ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model. Int J Cancer, 137, 698-709.

Nurden, A.T., Pillois, X., Fiore, M., Alessi, M.C., Bonduel, M., Dreyfus, M., Goudemand, J., Gruel, Y., Benabdallah-Guerida, S., Latger-Cannard, V., Negrier, C., Nugent, D., Oiron, R.D., Rand, M.L., Sie, P., Trossaert, M., Alberio, L., Martins, N., Sirvain-Trukniewicz, P., Couloux, A., Canault, M., Fronthroth, J.P., Fretigny, M., Nurden, P., Heilig, R. & Vinciguerra, C. (2015) Expanding the Mutation Spectrum Affecting alphaIIbbeta3 Integrin in Glanzmann Thrombasthenia: Screening of the ITGA2B and ITGB3 Genes in a Large International Cohort. Hum Mutat, 36, 548-561.

Riviere, E., Viallard, J.F., Guy, A., Kilani, B., Vieira-Dias, J., Pons, A.C., Couffinhal, T., Pellegrin, J.L. & James, C. (2015) Intrinsically impaired platelet production in some patients with persistent or chronic immune thrombocytopenia. Br J Haematol, 170, 408-415.

Tuffigo, M., Lazaro, E., James, C., Subtil, C., Viallard, J.F. & Fiore, M. (2015) Successful use of recombinant factor VIIa in a patient with acquired Glanzmann thrombasthenia. Haemophilia, 21, e116-118.